Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Deals·BioReference Health

Labcorp agrees to buy more of Opko's BioReference lab business for $722 million

The deal adds BioReference's clinical, women's health, urology and corrections testing, more than 80 patient service centers and the 4Kscore prostate test, with up to $150 million more tied to 4Kscore sales.

From Opko Health's Form 8-K filed Oct. 15, 2026, and the companies' Oct. 15 announcement as reported by MedTech Dive and Clinical Lab Products
The entrance to a Labcorp patient service center in Fort Worth, Texas, in 2023.
The entrance to a Labcorp patient service center in Fort Worth, Texas, in 2023. File photo.Aspensmonster / Wikimedia Commons (CC BY-SA 4.0)
Value
$722M
Type
Acquisition
Target
BioReference Health (select assets)
Buyer
Labcorp
Sector
Diagnostics
Announced
Oct. 15, 2026

Labcorp is going back to Opko Health for another piece of its BioReference Health lab business. The companies said Oct. 15 that Labcorp will pay $722 million in cash at closing for BioReference's clinical, women's health, urology and corrections testing operations, plus up to $150 million tied to future sales of the 4Kscore prostate cancer test.

Last year, Labcorp bought BioReference's oncology testing businesses for up to $225 million, a deal that added about $85 million to $100 million in annual revenue, MedTech Dive reported. This one is larger on both counts: Labcorp expects the newly acquired businesses to bring in about $250 million in revenue in their first year after closing. At $722 million, the upfront price is about 2.9 times that figure.

Why it matters: The deal folds a lab network that has historically concentrated on New York and New Jersey, according to MedTech Dive, into Labcorp's national system, along with more than 80 patient service centers. It also moves Opko further toward its biopharmaceutical business, which its chief executive said is where the company will now focus its resources.

According to Opko's Form 8-K, the asset purchase agreement was signed Oct. 14 among Opko, BioReference and Laboratory Corporation of America Holdings. The upfront price can move up or down depending on the acquired business's revenue at closing.

The earnout is where Labcorp's bet on 4Kscore shows up. Opko could receive up to $150 million in cash over as long as 10 years, depending on how much revenue Labcorp generates from the test, for total potential consideration of $872 million.

The deal has no financing condition, but it requires the Hart-Scott-Rodino antitrust waiting period to expire or be terminated, the filing says. Either side may end the agreement if the deal has not closed by April 14, 2027. If it is terminated in specified circumstances tied to a failure to get antitrust or other government approvals, Labcorp would owe Opko a $28.88 million fee.

Why 4Kscore draws attention

The companies describe 4Kscore as FDA-approved. The blood test is meant to help estimate, ahead of a biopsy decision, how likely it is that aggressive prostate cancer would be found. The companies said Labcorp's national scale would broaden access to the test.

Analysts focused on that test. Evercore ISI said the deal fits Labcorp's push into higher-growth specialty testing and that Labcorp's national reach could broaden 4Kscore's adoption, MedTech Dive reported. William Blair analysts called the test a "particularly compelling asset," according to the outlet.

Bryan Vaughn, Labcorp's executive vice president and president of diagnostics, said the deal "strengthens our ability to deliver affordable, high-quality, specialized diagnostic services to more patients and providers around the country."

What comes next

Opko chairman and chief executive Phillip Frost said the sale will let the company streamline its operations. Until closing, the two companies will keep running separately, without changing operations or services, they said.

The announcement does not say what, if anything, of BioReference will remain with Opko after this sale. The next marker is the antitrust waiting period, which has to run out before the April 14, 2027, date after which either side can walk away.

Sara Montes de Oca is the Editor in Chief of Charted. She previously worked as a correspondent and producer in Washington, D.C., covering business, finance, and politics. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Deals

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.